Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
NSCLC
atezolizumab
hyaluronanidase
pharmacokinetics
subcutaneous
Journal
Clinical pharmacology in drug development
ISSN: 2160-7648
Titre abrégé: Clin Pharmacol Drug Dev
Pays: United States
ID NLM: 101572899
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
13
11
2020
accepted:
17
02
2021
pubmed:
1
4
2021
medline:
23
2
2022
entrez:
31
3
2021
Statut:
ppublish
Résumé
Intravenous (IV) atezolizumab is approved for non-small cell lung and other cancers. Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase, a permeation enhancer for SC dispersion and absorption, is being developed to improve treatment options, reduce burden, and increase efficiency for patients and practitioners. IMscin001 (NCT03735121), a 2-part, open-label, global, multicenter, phase 1b/3 study, is evaluating the pharmacokinetics (PK), safety, and efficacy of SC atezolizumab. The part 1 (phase 1b) objective was determination of an SC atezolizumab dose yielding a serum trough concentration (C
Identifiants
pubmed: 33788415
doi: 10.1002/cpdd.936
pmc: PMC8518371
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
atezolizumab
52CMI0WC3Y
Banques de données
ClinicalTrials.gov
['NCT03735121']
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1142-1155Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Références
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Lancet. 2020 Jun 13;395(10240):1835-1844
pubmed: 32534646
Int J Cancer. 2020 Oct 1;147(7):1963-1969
pubmed: 32141617
MAbs. 2016;8(3):593-603
pubmed: 26918260
Br J Clin Pharmacol. 2015 Nov;80(5):1001-9
pubmed: 25900065
Lancet Oncol. 2014 Mar;15(3):343-52
pubmed: 24521993
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
Drug Res (Stuttg). 2014 Nov;64(11):569-75
pubmed: 24452524
Drug Deliv. 2019 Dec;26(1):98-106
pubmed: 30744432
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Cancer Med. 2016 Mar;5(3):389-97
pubmed: 26806010
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
J Clin Pharmacol. 2019 May;59(5):702-716
pubmed: 30570763
BioDrugs. 2018 Oct;32(5):425-440
pubmed: 30043229
Geburtshilfe Frauenheilkd. 2014 Apr;74(4):343-349
pubmed: 25076790
Arzneimittelforschung. 2012 Sep;62(9):401-9
pubmed: 22918857
J Am Coll Radiol. 2020 Jul;17(7):845-854
pubmed: 32485147
Eur J Cancer. 2017 Sep;82:230-236
pubmed: 28648618
Ann Oncol. 2017 Apr 1;28(4):836-842
pubmed: 28031173
Clinicoecon Outcomes Res. 2016 May 23;8:227-33
pubmed: 27284260
Breast Cancer Res Treat. 2020 May;181(1):97-105
pubmed: 32240454
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Am Med Dir Assoc. 2021 Jan;22(1):50-55.e6
pubmed: 32674952
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Can Oncol Nurs J. 2019 Oct 1;29(4):267-270
pubmed: 31966017
Lancet Haematol. 2020 Aug;7(8):e559
pubmed: 32735833
Eur J Cancer. 2017 Nov;86:82-90
pubmed: 28963915
J Comp Eff Res. 2018 May;7(5):411-419
pubmed: 29199854
Clin Pharmacol Ther. 2019 Feb;105(2):486-495
pubmed: 30058723
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
Oncotarget. 2017 Jun 16;8(46):81343-81349
pubmed: 29113393
JAMA Oncol. 2019 May 1;5(5):e190339
pubmed: 30998824
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Clin Pharmacol Ther. 2017 Aug;102(2):305-312
pubmed: 27981577
J Hosp Med. 2015 Jul;10(7):471-8
pubmed: 25755150
Cancer Chemother Pharmacol. 2019 Dec;84(6):1257-1267
pubmed: 31542806
Cancer Treat Rev. 2020 Aug;88:102063
pubmed: 32623296
Clin Transl Oncol. 2017 Dec;19(12):1454-1461
pubmed: 28577152
Eur J Cancer. 2017 Sep;82:237-246
pubmed: 28625777
J Immunother Cancer. 2019 Nov 21;7(1):314
pubmed: 31753029
Future Oncol. 2019 Oct;15(28):3267-3281
pubmed: 31394933
ESMO Open. 2020 Apr;5(2):e000765
pubmed: 32245904
Ann Oncol. 2014 Oct;25(10):1979-1987
pubmed: 25070545
Lancet Haematol. 2017 Jun;4(6):e272-e282
pubmed: 28476440